Titan Pharmaceuticals Schedules Conference Call to Review

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, CA--(Marketwired - May 4, 2016) - Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced that it will host a live conference call at 4:15 p.m. EDT / 1:15 p.m. PDT on Tuesday, May 10, 2016 to discuss the company's financial results as of March 31, 2016. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman. Highlights of the first quarter will be included in a press release to be issued prior to the call.

The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com . The call can also be accessed by dialing 800-279-9534 , participant code 6051842, five minutes prior to the start time. A replay of the call will be available on the company website approximately two hours after completion of the call and will be archived for two weeks.

About Titan Pharmaceuticals Titan Pharmaceuticals Inc. ( NASDAQ : TTNP ), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com .

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT: Titan Pharmaceuticals, Inc.: Sunil Bhonsle President & CEO (650) 244-4990 Investors: Stephen Kilmer (650) 989-2215 skilmer@titanpharm.com Media: Susan Thomas (650) 989-2216 sthomas@titanpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 148

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 112

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 26

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 86

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading

Top 5 Most Recently Viewed Articles

Evogene Partners with Academic Leader to Combat Metabolic Disorders

Updated Category News Views 174

Evogene's Innovative Collaboration Evogene Ltd. (NASDAQ: EVGN) has entered into an exciting partnership with Professor Ehud Gazit from Tel Aviv University to develop innovative therapeutics aimed at metabolic diseases. Understanding Metabolic Diseases Metabolic diseases often arise from the inability of the body to break down specific metabolites. This inability can lead...

Continue Reading
Farasis Energy's Rise in Solid-State Battery Rankings Explained

Updated Category News Views 505

Farasis Energy's Notable Achievement in Battery Technology Recently, Farasis Energy gained recognition as a leading contender in the 2024 China Solid-State Battery Competitiveness Rankings, marking a significant milestone in the company's journey. As a global frontrunner in electric vehicle (EV) battery solutions, Farasis Energy has established robust partnerships with...

Continue Reading
Building a Reliable Future with Weilliptic's Advanced AI

Updated Category News Views 310

Weilliptic: Pioneering Autonomous and Trustworthy AI In the rapidly evolving landscape of technology, Avinash Lakshman, a serial entrepreneur renowned for creating Amazon Dynamo and Apache Cassandra, is leading the charge towards a new foundational infrastructure that merges AI and blockchain into a cohesive and verifiable framework. This innovative platform, known as...

Continue Reading
Navigating Investor Rights: Aehr Test Systems Case Insights

Updated Category News Views 169

Aehr Test Systems Investor Rights and Securities Fraud Lawsuit Investors in Aehr Test Systems (NASDAQ: AEHR) find themselves at a critical juncture. The Rosen Law Firm, renowned for its advocacy on behalf of investors, has issued important reminders regarding a securities fraud lawsuit that centers on Aehr Test Systems. Understanding the Class Period The timeline for this...

Continue Reading
Understanding Andersons' Earnings and Market Performance Insights

Updated Category News Views 276

Anticipating Earnings from Andersons Inc Andersons Inc (NASDAQ: ANDE) is gearing up to share its quarterly earnings report soon. This announcement is of considerable interest to both existing shareholders and potential investors. It's vital to stay informed about what to expect before the company reveals its financial results. Projected Earnings and Market Sentiments...

Continue Reading